News Story: Full Text
Sponsored By
Cleveland Clinic Brain Tumor and Neuro-Oncology Center
Please Click On The Above Banner For More Details
Braintumor Website


TheraCIM h-R3 to Start Phase I/II in New Indication (PR Newswire)YM BioSciences Inc. announced today that the Health Products & Food Protection Branch of Canada has approved YMB`s IND to conduct a phase I/II study of its EGF receptor antibody, TheraCIM h-R3, in conjunction with radiotherapy in patients with brain cancer resulting from metastases from non-small cell lung cancer.- Jul 10 4:10 PM ET

IF the story does not appear below, Click HERE to view the text of the story!
Note: The original website is displayed below - we have no control over it and are not responsible for the content of it, we just report it! IF you click on anything below, it will take you off of our website!
Original Source:

(Everything below this line is from!)

Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557